USP35 activated by miR let-7a inhibits cell proliferation and NF-κB activation through stabilization of ABIN-2

作者：Liu, Chunyan; Wang, Lina; Chen, Weiwen; Zhao, Shihu; Yin, Chunli; Lin, Yani; Jiang, Anli; Zhang, Pengju^*

来源：Oncotarget, 2015, 6(29): 27891-27906.

DOI：10.18632/oncotarget.4451

• ABIN-2
• deubiquitylase
• miR let-7a
• NF-kappa B
• USP35

Ubiquitin specific protease 35 (USP35) is a member of deubiquitylases (DUBs). It remains largely unknown about the biological role and the regulation mechanism of USP35. Here, we first identified miR let-7a as a positive regulator of USP35 expression and showed that USP35 expression positively correlates with miR let-7a expression in different cancer cell lines and tissues. Then, we showed that USP35 expression was decreased dramatically in the tumor tissues compared with the adjacent non-cancerous tissues. USP35 overexpression inhibited cell proliferation in vitro and inhibited xenograft tumor growth in vivo. Furthermore, we revealed that USP35 acts as a functional DUB and stabilizes TNFAIP3 interacting protein 2 (ABIN-2) by promoting its deubiquitination. Functionally, both ABIN-2 and USP35 could inhibit TNF alpha-induced NF kappa B activation and overexpression of ABIN-2 alleviated USP35-loss induced activation of NF-kappa B. Collectively, our data indicated that miR let-7a-regulated USP35 can inhibit NF-kappa B activation by deubiquitination and stabilization of ABIN-2 protein and eventually inhibit cell proliferation. Overall, our study provides a novel rationale of targeting miR let-7a-USP35-ABIN-2 pathway for the therapy of cancer patients.

• 出版日期2015-9-29
• 单位山东大学